Mental Disorders
643 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg) + Placebo for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg) + Placebo for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| [F-18]Flornaptitril for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 100 mg for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 40 Hz sound stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 40 Hz Synchronous Audio-Visual Stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 50 mg qhs for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AADvac1 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AADvac1 for pick disease of the brain | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AB-1001 Gene Therapy for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Abbott Laboratories Infinity™ implantable deep brain stimulation system for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Academic Competency Enhancement (ACE) classroom for attention deficit disorder with hyperactivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Accelerated protocol of home Transcranial direct current stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Accelerated theta-burst stimulation treatment for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Accelerated theta-burst stimulation treatment for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acceptance and Commitment Therapy + Ketamine for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acceptance-Based Behavior Therapy (ABBT) for anxiety disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acetylcysteinamide for dementia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Activa Tremor Control Sys (DBS Implant) for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Activa Tremor Control Sys (DBS Implant) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active - Conventional tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active - HD tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| active rTMS treatment for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| active rTMS treatment for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| active tDCS + mindfulness meditation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| active tDCS stimulating left DLPFC for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active tDCS with Sternberg task for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active tDCS with Sternberg task for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active transcranial direct current stimulation for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active Whole-Body Hyperthermia (Active WBH) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acupuncture for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| acupuncture (strong reaction acupoints) + SSRIs for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| acupuncture (weak reaction acupoints) + SSRIs for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| acupuncture + placebo for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| acupuncture + SSRIs for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| acupuncture and moxibustion for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AD04 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AD5-NCOV for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Administer Leqemi 10 mg/kg, every two weeks. for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aducanumab for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Aducanumab for cognitive dysfunction | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aerobic exercise intervention for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aia for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Ambroxol for dementia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ambroxol hydrochloride for lewy body disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amygdala neurofeedback for borderline personality disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| App AURORA (Digital Therapy) + conventional treatment for generalized anxiety disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Arbaclofen for autism spectrum disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aripiprazole for bipolar disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aripiprazole for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Aripiprazole for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aripiprazole for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Aripiprazole + IEM (Ingestible Event Marker) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aripiprazole + IEM (Ingestible Event Marker) for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Art and physical activity program. for anxiety disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aticaprant for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| ATTN201 Focused Ultrasound to the CMN for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATTN201 Focused Ultrasound to the CMN for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atuzaginstat for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Audiovisual stimulation VR system for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Audiovisual stimulation VR system for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Auricular Acupuncture for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azetukalner for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Baclofen for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Baclofen for anxiety disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BBB opening for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Behavioral Activation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Behavioural Activation (BA) Therapy for bipolar disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Behavioural Activation (BA) Therapy for depressive disorder, treatment-resistant | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Behavioural Activation (BA) Therapy for major depressive disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Benzocaine Gel applied to the cervix + Hydroxyzine Hydrochloride for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bexicaserin for neurodevelopmental disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bilateral implantation of DBS system to Habeluna for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood Brain Barrier (BBB) Disruption for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Blue-depleted evening light condition for mental disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BPL-003 for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Brenipatide for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Brenipatide for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brief Cognitive Behavioral Conjoint Therapy (bCBCT) + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brief cognitive task-based intervention for psychological trauma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brief cognitive task-based intervention for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brief Negotiation Interview for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brief Negotiation Interview + Naltrexone + Gabapentin for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Buntanetap for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Buntanetap tartrate for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Buntanetap tartrate for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bupropion + Escitalopram + Venlafaxine + SERTRALINE for bipolar disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bupropion + Escitalopram + Venlafaxine + SERTRALINE for major depressive disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bupropion + Escitalopram + Venlafaxine + SERTRALINE for schizophrenia | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cabotegravir for substance-related disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cal-Mag Butyrate for cognition disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for marijuana abuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cannabidiol for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cannabidiol + Dronabinol for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet + Naproxen 500 Mg + Opioids for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CBCT + Therapy + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cca for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cervical Lymphatic Microsurgery for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cervical Lymphaticovenous and Lymph Node-to-Vein Anastomosis for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Chlorhexidine for erectile dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cholecalciferol for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cholecalciferol for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| chronobiological augmentation for bipolar disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| chronobiological augmentation for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CI-581a for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CI/BNST stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CI/BNST stimulation + ITP Stimulation + No stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CI/BNST stimulation + No stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clinical assessment + salivary collections of amylase and cortisol + Stress elicitation experiment + Structural and Functional MRI for borderline personality disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clozapine for bipolar disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clozapine for major depressive disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clozapine for schizophrenia | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Behavioral Therapy (CBT) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Behavioral Therapy (CBT) + Whole-Body Hyperthermia for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Behavioral Therapy (CBT) + Whole-Body Hyperthermia (WBH) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Behavioral Therapy + Psilocybin for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Processing Therapy for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive task + Left DLPFC tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive task + Right DLPFC tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Training for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Training + Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combination of Neostigmine and Glycopyrrolate + I-Box by Dynatronics for encopresis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combined LAI Treatment: Cabenuva and Sublocade for opioid-related disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combined metabolic activators for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Communication Bridge™ for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Communication Bridge™ for aphasia, primary progressive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Contingency management for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Counseling + Biospecimen Collection + Interview + Survey Administration + Psilocybin for depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Counseling + Quitting using Medication for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Counseling + Switching to E-Cigarette for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Crisugabalin for generalized anxiety disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Curcumin for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Curcumin and Fluoxetine for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyclobenzaprine hydrochloride for stress disorders, traumatic, acute | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| D-Cycloserine (DCS) for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| D-Cycloserine (DCS) for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Daoib for dementia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Daridorexant for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dbs for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dbs for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DBS + No Stimulation (Sham) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DBS of the NAc for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DBS system for obsessive-compulsive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DC-LVA treatment plus usual care for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Simulator for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation for anorexia nervosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation for autistic disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation for gambling | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Deep Brain Stimulation for obsessive-compulsive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Deep Brain Stimulation for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation (DBS) for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation Model 3387 Model 3389 for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation Model 3387 Model 3389 for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| deep brain stimulation with short & long pulse width for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| deep brain stimulation with short & long pulse width for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| deep brain stimulation with short & long pulse width for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation, DBS for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation, implanted for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep brain stimulation(Active) + Deep brain stimulation(Sham) for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep brain stimulation(Active) + Deep brain stimulation(Sham) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation(DBS) + Esketamine for depressive disorder, treatment-resistant | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymph node to venous bypass (DCLNV-BP) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymphatic-venous anastomosis for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymphatic-venous anastomosis, LVA for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphaticovenous Anastomosis(DLVA) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphaticovenous Anastomosis(DLVA) for lewy body disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical lymphatlc-Venous Anastomosis Surgery for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymphovenous anastomosis (LVA) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphovenous Anastomosis + Routine Treatment for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphovenous Anastomosis + Routine Treatment for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Device-only fitting for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Device-only fitting for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Device: Directional Deep Brain Stimulation for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexmedetomidine hydrochloride for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexmedetomidine hydrochloride for stress disorders, traumatic, acute | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dextromethorphan and Bupropion Sustained-Release Tablets for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diamorphine hydrochloride anhydrous for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet-as-Usual (DAU) + LCHF Ketogenic Diet for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet-as-Usual (DAU) + LCHF Ketogenic Diet for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet-as-Usual (DAU) + LCHF Ketogenic Diet for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dietary vitamin D for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dimethyltryptamine for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Divalproex sodium for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Donanemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Donanemab for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Donanemab for lewy body disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab + 2-Pyrazinecarboxamide, N-[3-[(4aR,7aS)-2-amino-6-(5-fluoro-2-pyrimidinyl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl]-4-fluorophenyl]-5-methoxy- for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab + Dexamethasone for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab + Nivegacetor for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Double Active: Active portable transcranial stimulation (ptES) and active internet-based behavioral therapy (iBT) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dronabinol for marijuana abuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTT106 for erectile dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DynamiCare Health for opioid-related disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| E-Cigarette 7.2 mg nicotine for tobacco use disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EB-1020 (Centanafadine) high dose for attention deficit disorder with hyperactivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EB-1020 (Centanafadine) low dose for attention deficit disorder with hyperactivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ecig 24 mg nicotine for schizophrenia | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| edupression.com® for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| edupression.com® for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EEG-based personalized TMS for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Electroacupuncture for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Electroacupuncture for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| electronic cigarette for tobacco use disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elunetirom for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Emestedastat for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Emono for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Emraclidine for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Endd (njoy) for tobacco use disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Escitalopram + Esketamine + Venlafaxine + Duloxetine + SERTRALINE for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Esketamine for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Esketamine for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for bipolar disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for schizophrenia | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Esketamine Treatment as Usual (ESK) + Virtual-Reality-based mindfulness intervention for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Esketamine Treatment as Usual (ESK) + Virtual-Reality-based mindfulness intervention for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Esomeprazole for autistic disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Estradiol for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Etanercept for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Evenamide 15 mg bid for schizophrenia, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ExAblate 4000 Type 2.1 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for cognitive dysfunction | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exercise + Control for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Experimental regimen for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Facilitate tDCS + CR for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Facilitate tDCS + CR for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Facilitate tDCS + CR for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fasedienol for phobia, social | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Fasudil for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fasudil for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplant (FMT) for attention deficit disorder with hyperactivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplant (FMT) + Vancomycin + NITAZOXANIDE for attention deficit disorder with hyperactivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Flibanserin for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 11 |
| FLUOROETHOXYBENZOVESAMICOL F-18 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine for depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Fluoxetine for obsessive-compulsive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine + Dextromethorphan for body dysmorphic disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine + Dextromethorphan for obsessive-compulsive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine + Imipramine for dysthymic disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine + Imipramine for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Focused Transcranial Ultrasound for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Focused Transcranial Ultrasound for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Full Dose Midomafetamine HCl for stress disorders, post-traumatic | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gam-COVID-Vac for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GammaSense Stimulation device for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gantenerumab for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| GENUS device (Active Settings) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GENUS device (Active Settings) for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ginkgo for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program for bipolar disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + naltrexone and bupropion (combination) for bipolar disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + naltrexone and bupropion (combination) for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + Phentermine-Topiramate for bipolar disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + Phentermine-Topiramate for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + Semaglutide for bipolar disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + Semaglutide for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GV-971 for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| GV-971 + MEMANTINE for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GXV-813 for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hatha Yoga Practice Group for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HB-1 for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Healthy Activity Program (HAP) for depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Heart to Heart Yoga for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High doses of Thiamine y Biotin for huntington disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High intensity whole-body infrared heating for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| High Monetary Incentive (HMI) + Message-Based Psychotherapy (MBP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High Monetary Incentive (HMI) + Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High Monetary Incentive (HMI) + Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High Monetary Incentive (HMI) + Video-Chat Psychotherapy (VCP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High THC Cannabis for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High THC Cannabis for marijuana abuse | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High THC Cannabis for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity inpatient MDMA-assisted psychotherapy for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity Mediterranean diet intervention for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HS-10380 for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| hUC-MSC-Exos Nasal Spray for autism spectrum disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| human Mesenchymal Stem Cells for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| human Mesenchymal Stem Cells for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxyzine Hydrochloride for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxyzine Hydrochloride + Lidocaine for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hyperbaric Oxygen Therapy for combat disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ibogaine hydrochloride for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Iclepertin for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Increasing control over stimulant use and physical health through incentivized rehabilitation for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Individualized rTMS (transcranial magnetic stimulation) for depressive disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Integration Therapy for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Integration Therapy for dissociative disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) + METHYLPHENIDATE HYDROCHLORIDE for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intra-striatal rAAV5-miHTT for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| intracavernous platelet rich plasma therapy for erectile dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ITI-1284 10 mg for generalized anxiety disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ITI-1284 20 mg for generalized anxiety disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ITP Stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JNJ-64042056 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarX-EC + KarXT for autism spectrum disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarX-EC + KarXT for autistic disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarX-EC + KarXT for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarXT for autistic disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarXT for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine for cocaine-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ketamine for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ketamine for stress disorders, post-traumatic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine Hydrochloride for alcoholism | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine Hydrochloride for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine Hydrochloride for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine Hydrochloride for stress disorders, post-traumatic | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine-Assisted Psychotherapy (KAP) for anxiety disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine-Assisted Psychotherapy (KAP) for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Ketogenic Diet for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ketogenic Diet for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ketogenic Diet for psychotic disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet + Non-ketogenic Diet for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic diet intervention for psychotic disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic diet intervention for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic foodstuffs for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Therapy for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| kudzu extract, puerarin for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lacosamide for bipolar disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LCHF Ketogenic Diet for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lecanemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Lecanemab for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| LECANEMAB + Etalanetug for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Left DLPFC tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Leucovorin for asperger syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Leucovorin for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Leucovorin for autistic disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Levoleucovorin calcium for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Lifus for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| light box + Wake Therapy + LITHIUM for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| light box + Wake Therapy + LITHIUM for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lithium for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Lithium carbonate + perospirone hydrochloride for depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lithium sulphate prolonged-release 660 mg for bipolar disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| low intensity focused ultrasound (LIFU) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low Monetary and Alternative Incentive (LMAI) + Message-Based Psychotherapy (MBP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low Monetary and Alternative Incentive (LMAI) + Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low Monetary and Alternative Incentive (LMAI) + Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low Monetary and Alternative Incentive (LMAI) + Video-Chat Psychotherapy (VCP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-intensity focused ultrasound for cocaine-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-intensity focused ultrasound for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-Intensity Focused Ultrasound + Low-Intensity Focused Ultrasound - sham for anxiety disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-Intensity Focused Ultrasound + Low-Intensity Focused Ultrasound - sham for opioid-related disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lurasidone for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY-2599666 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY-2599666 for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3002813 for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3002813-IV for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3002813-SC for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lysergide d-tartrate for attention deficit disorder with hyperactivity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lysergide d-tartrate for generalized anxiety disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Mad for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Magnesium for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents + Neuronavigation-guided single-element focused ultrasound transducer + Positron Emission Tomography (PET) + FLORBETAPIR F-18 + PERFLUTREN for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Manualized therapy + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Manualized therapy + Midomafetamine HCl for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matched Placebo (oral gummy) + Δ9-Tetrahydrocannabivarin (oral gummy) for tobacco use disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Intramuscular Placebo + IBOGAINE HYDROCHLORIDE for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo (E2814) + LECANEMAB for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MDMA Assisted Therapy for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MDMA Assisted Therapy for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mdma-at for combat disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mdma-at for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Activa PC+S System for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Activa SC DBS, Lead Model 3387 for depressive disorder, treatment-resistant | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Percept PC DBS system for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Percept PC DBS system for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic SenSight Directional DBS lead for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Summit RC+S DBS system for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Summit RC+S DBS system for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Memantine for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| MEOPA (Nitrous Oxide/Oxygen Premix) for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Message-based psychotherapy (MBP) for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Message-based psychotherapy (MBP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Message-Based Psychotherapy (MBP) + Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Message-Based Psychotherapy (MBP) + Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy + Video-Chat Psychotherapy (VCP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy + Video-Chat Psychotherapy (VCP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metformin hydrochloride for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Methylphenidate hydrochloride for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Methylphenidate hydrochloride for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mevidalen for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midazolam Placebo Solution + Esketamine for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midomafetamine for adjustment disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midomafetamine for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Midomafetamine for combat disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midomafetamine for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 18 |
| Midomafetamine for substance-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midomafetamine HCl for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Midomafetamine Hydrochloride for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindfulness-Based Stress Reduction for agoraphobia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindfulness-Based Stress Reduction for generalized anxiety disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindfulness-Based Stress Reduction for panic disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindfulness-Based Stress Reduction for phobia, social | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindfulness-centered psilocybin-assisted therapy + Music-centered psilocybin-assisted therapy + Psilocybin for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindset for alcohol-related disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MK-1167 for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| ML-007C-MA for psychotic disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ML-007C-MA for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Moderate doses of Thiamine y Biotin for huntington disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Modified deep cervical Lymphatic-Venous Anastomosis for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MR guided low intensity focused ultrasound for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Music & Auditory Beat Stimulation for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Music and Theta Auditory Beat Stimulation for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Music Therapy for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NanoLithium® NP03 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Navigate for affective disorders, psychotic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Navigate for psychotic disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Navigate for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Navigate for schizophrenia, childhood | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NBI-1117570 for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Next Generation Dome Helmet (NGDH) for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotinamide Riboside (NR) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotinamide Riboside (NR) for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nightmare Deconstruction and Reprocessing for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NightWare for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| NightWare smartwatch configured to detect physiological signs of sympathetic activation during sleep, such as heart-rate spikes and movement patterns. for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NightWare Therapeutic System for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| NightWare Therapeutic System for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Nitrous Oxide for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Nitrous Oxide for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Nivegacetor for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nmdae for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nmdae for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NMDAE plus AIFA for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NMS-01 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Obicetrapib 10 mg for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oculus VR headset for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Olanzapine for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Olanzapine and Fluoxetine combination (OFC) for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Olz/sam for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| omega-3 for antisocial personality disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Omega-3 supplemented drink for antisocial personality disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| one night of sleep deprivation and two FDG PET scans for bipolar disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| one night of sleep deprivation and two FDG PET scans for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ORG-34517 for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OT-led Exercise Group for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oxcarbazepine for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oxytocin for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pemvidutide for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Perospirone hydrochloride tablets for depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PHEN/TPM ER (Qsymia®) for binge-eating disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + ADUCANUMAB for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Placebo + ADUCANUMAB for cognitive dysfunction | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Donanemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Escitalopram + Venlafaxine + Duloxetine + SERTRALINE for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Nimodipine for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Psilocybin for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Psilocybin + Propofol for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + SRP-1005 for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| placebo 2 tablets qhs for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo Nasal Spray for phobia, social | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Placebo Nasal Spray - Placebo Nasal Spray for phobia, social | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo of trazodone + Psilocybin for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prolonged Exposure + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prolonged exposure therapy + MIDOMAFETAMINE for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prolonged exposure therapy + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Propranolol for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Propranolol for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psa for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 8 |
| Psilocybin for anxiety disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Psilocybin for bipolar disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for borderline personality disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for cocaine-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 8 |
| Psilocybin for generalized anxiety disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 19 |
| Psilocybin for obsessive-compulsive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Psilocybin for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Psilocybin + MBCT therapy for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + Modafinil for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + PIMAVANSERIN for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + PIMAVANSERIN + Modafinil for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + Placebo for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + ZOLPIDEM for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + ZOLPIDEM + Modafinil for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + ZOLPIDEM + PIMAVANSERIN for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + ZOLPIDEM + PIMAVANSERIN + Modafinil for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychopharmacological treatment for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychotherapy for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychotherapy + Medication for opioid use disorder for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychotherapy + MIDOMAFETAMINE for combat disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychotherapy + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Psychotherapy + Survey Administration + Psilocybin for anxiety disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Questionnaires for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Questionnaires for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Quetiapine for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Randomized, staggered withdrawal phase for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Randomized, staggered withdrawal phase for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| real-time fMRI neurofeedback training for cocaine-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| real-time fMRI neurofeedback training + Ketamine for cocaine-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Receive tDCS+CR for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Receive tDCS+CR for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Receive tDCS+CR for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for dementia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recovery Management Checkups (RMC) delivered by community-based agencies (RMC adopters) for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recovery Management Checkups (RMC) delivered by community-based agencies (RMC adopters) for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relapse prevention cognitive behavioral therapy (CBT) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| REPAIR Sleep for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| REPAIR Sleep for cognition disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RGH-202 for phobia, social | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Right DLPFC tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Risperidone for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Risperidone for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Rituximab for psychotic disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RP902 for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| rTMS treatment + Ketamine for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S1B-408 for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Saccharomyces cerevisiae for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sea-it for combat disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sea-it for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semagludtide for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Sense4Safety for cognitive dysfunction | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sertraline for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| sertraline, lithium for bipolar disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| sertraline, lithium for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Service-only Fitting for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Service-only Fitting for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| sex therapy + Flibanserin for sexual dysfunctions, psychological | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SGB - Combined Solution of Bupivacaine + Ketamine Adjuvant for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| sham acupuncture + SSRIs for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Sham neurofeedback for borderline personality disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Shuganjieyu capsule for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Simple cognitive task for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Simufilam for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| SmartSleep EEG recording headband + Ketamine for stress disorders, post-traumatic | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium lactate for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 600mg for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 600mg for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 900mg for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 900mg for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium Oligomannate Capsules for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solanezumab for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Solanezumab for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solizmestrocel for erectile dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solriamfetol for binge-eating disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SPT-300 for anxiety disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SPT-300 for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SSRI/SNRI + Esketamine for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SSRI/SNRI + Esketamine for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| STAM 1100mAh CE4 eGo Clearomizer for tobacco use disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Standardized kudzu for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®) with the Magnus Neuromodulation System for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Step count goal for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Stimulation-ON for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured Integrated Reframing Therapy (SIRT) for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured Integrated Reframing Therapy (SIRT) for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured Integrated Reframing Therapy (SIRT) + Psilocybin for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured Integrated Reframing Therapy (SIRT) + Psilocybin for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Supermicrosurgical Lymphaticovenular Anastomosis (LVA) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Supportive psychotherapy + Psilocybin for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Supportive psychotherapy + Psilocybin + MICROCRYSTALLINE CELLULOSE for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tACS combined with 40 Hz sound stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Task-oriented resistance exercise for cognitive dysfunction | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TAU+CBT for pts+Family Intervention+CM. for affective disorders, psychotic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TAU+CBT for pts+Family Intervention+CM. for psychotic disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tDCS for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| TDCS - transcranial direct current stimulation for anxiety disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tDCS (Eldith DC-Stimulator (CE certified)) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| tDCS over DLPFC for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tDCS over DLPFC for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Testosterone undecanoate for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Therabot for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Therabot for feeding and eating disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Therapy + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Tirzepatide for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Tominersen for huntington disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Transcranial alternating current stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcranial Direct Current Stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| transcranial direct current stimulation (tDCS) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcranial direct current stimulation (tDCS) on the Left DLPFC for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcranial direct current stimulation (tDCS) on the right VLPFC for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcranial Direct Current Stimulation + SERTRALINE for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| transcranial magnetic resonance guided focused ultrasound BBB disruption for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trazodone 5mg + Psilocybin for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TREATMENT ARM: Full dose for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TREATMENT ARM: Full dose for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treatment with Ketone Supplement for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treatment with Placebo for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tributyrin for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tributyrin for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Troculeucel for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trontinemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Trontinemab for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tsa for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TTYP01 Tablets (12mg or 18mg) for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ulotaront for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Umblical Cord-Derived Mesenchymal Stem Cell-Derived Exosomes for erectile dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valacyclovir for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valacyclovir for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valiltramiprosate for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valproic acid for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Vancomycin + NITAZOXANIDE for attention deficit disorder with hyperactivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Varenicline for marijuana use | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Varenicline for tobacco use disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Venlafaxine for generalized anxiety disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vericiguat for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Video-chat Psychotherapy (VCP) for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Video-chat Psychotherapy (VCP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Viloxazine hydrochloride for attention deficit disorder with hyperactivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Visuospatial Task (VST) for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vitamin d for seasonal affective disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vitamin D 100 micrograms for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Votoplam (blinded) for huntington disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VR social musical exergame for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VR solo musical exergame for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Walk-and-talk therapy for anxiety disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wbh for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Whole-Body Hyperthermia for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Whole-Body Hyperthermia for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Whole-body hyperthermia + standard medical care for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wujia Yizhi granules for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wysa Digital Chatbot Program for [obsolete] disordered eating behavior | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Xanomeline Enteric Capsule + Xanomeline/Trospium Chloride Capsule for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Xiaochaihu Granules (Low Dose) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Xingqi Daozhi Decoction for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Yband(YDT-201N) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ziprasidone for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zonisamide for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |